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Melioidosis is a severe and frequently fatal disease caused by an
environmental bacterium, Burkholderia pseudomallei, that is wide-
spread throughout the tropics. It is estimated to affect approximately
165,000 people every year and kill 89,000 of them [1]. Despite this, it
remains little known, even in countries in which it is endemic, and
the burden of infection is significantly underestimated by national
surveillance systems [2,3]. It is so neglected that it does not even fea-
ture in official lists of Neglected Tropical Diseases (NTD) even though
it is believed to cause loss of more disability-adjusted life years than
many diseases formally recognised as NTDs [4].
In this issue of EBioMedicine, Madden and colleagues report the
development of a tool, which they call ARDaP, for detecting antimi-
crobial resistance (AMR) determinants in next generation sequencing
(NGS) data for B. pseudomallei, having found shortcomings with exist-
ing tools for this purpose [5]. They found that ARDaP accurately
detected all the previously described SNP, indel, CNV, inversion, and
gene loss AMR determinants in the B. pseudomallei isolates studied,
and accurately predicted three previously undescribed determinants.
In comparison, other commonly-used tools such as CARD, ResFinder
and AMRFinderPlus failed to find any of the clinically-relevant var-
iants in B. pseudomallei, and found only the intrinsic resistance genes
present in all B. pseudomallei strains.
In many ways, B. pseudomallei was a strange choice of organism
for this study, reflecting the prior research interests of the authors.
Although it is a species that is intrinsically resistant to many antibiot-
ics which has a large and highly plastic genome organised in two
chromosomes, and exhibits frequent horizontal gene acquisition [6],
probably reflecting its need to adapt to competition within itsE-mail address: david.d@tropmedres.ac (D.A.B. Dance).
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amongst patients being treated for melioidosis as it is for many other
infections [7]. The reason for this is probably two-fold. First, although
resistance does occur in a minority of melioidosis patients during
treatment, this is always a result of chromosomal mutations, and
plasmid-mediated transferrable resistance, such as occurs amongst
Enterobacterales for example, has never been reported [8]. Secondly,
person-to-person spread of B. pseudomallei has rarely if ever been
seen, and so even when resistance does develop it is an evolutionary
dead end. In addition, whilst ARDaP may be an extremely efficient
way of detecting AMR determinants in B. pseudomallei, it is unlikely
to be applicable in the majority of clinical laboratories that serve the
poor, rural populations in the developing world that are most likely
to suffer frommelioidosis, at least for the foreseeable future.
In fact, the most important aspect of the study of Madden et al. is
the potential for this approach to be adapted for use with any bacterial
species which, like B. pseudomallei, may not be included any datasets
used to test AMR tools. There are many existing tools for determining
AMR from sequencing data [9], but this study demonstrates that they
are not all suitable for detecting resistance mechanisms in pathogens
where resistance is caused by a wide spectrum of mutations. In addi-
tion, ARDaP is able to identify minor allele variants, enabling the pre-
diction of AMR from samples where a single colony cannot be
obtained, and to flag previously unknown potential AMR determinants
for further investigation, a useful addition for species in which knowl-
edge of AMR determinants is incomplete. While the components of
this bioinformatic pipeline are all individually available, ARDaP com-
bines them in an open-source package which produces a single user-
friendly report, which will be invaluable for non-specialist bioinforma-
ticians. However, accurate detection of B. pseudomallei resistance
determinants required Madden et al. to develop a custom database for
this species. To extend the use to other species will require substantial
effort to curate catalogues of species-specific resistance variants, and
to make those available to the scientific community, as has been done
for other widely used AMR databases [10]. A further barrier to the
adoption of NGS as a tool for use with pathogens predominantly iden-
tified in resource-limited settings is that these databases can only be
as comprehensive as the number of phenotypically-characterised
strains available permits. Detailed phenotyping and sequencing are
not routinely performed in these settings, as can be seen from ther the CC BY license (http://creativecommons.org/licenses/by/4.0/)
2 D.A.B. Dance and E.M. Batty / EBioMedicine 63 (2021) 103178limited number of strains available to Madden et al. despite the high
burden of B. pseudomallei disease. Despite these limitations, ARDaP
represents an important step towards incorporating AMR detection
from NGS into routine clinical practice in the future.Contributors
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